FDA Advances Leucovorin for Autism-Related Folate Differences, While Core Trait Supports Remain Limited

Addressing a Metabolic Difference in Some Cases

The FDA announced in September 2025 it was advancing approval for leucovorin calcium tablets to treat cerebral folate deficiency (CFD) in autistic individuals. CFD occurs when the body has difficulty transporting folate (a B vitamin crucial for brain function) across the blood-brain barrier. This metabolic difference is present in an estimated 5-10% of autistic individuals according to 2026 research in Nature, though some clinicians suspect milder folate transport variations may be more widespread.

Navigating Off-Label Prescribing Trends

Despite limited large-scale evidence, leucovorin's off-label use for broader autism-related traits has grown significantly, as Medical Xpress reported in May 2026. Some families report improvements in communication when using the drug, like the case described in the Journal of Health Economics and Outcomes Research where a nonverbal child began using words. However, these remain anecdotal without controlled studies. An ongoing clinical trial (NCT02839915) is investigating leucovorin's potential effects on language differences in autism, with results expected in 2027.

An ongoing clinical trial (NCT02839915) is investigating leucovorin's potential effects on language differences in autism, with results expected in 2027.

The Support Gap for Core Traits

Only two medications — risperidone and aripiprazole — are FDA-approved for autism, and these primarily address distress responses like emotional dysregulation rather than core social or communication patterns. As noted by Autism.org's psychopharmacology resource, this leaves many autistic individuals and families seeking alternative supports. Some turn to behavioral therapies, assistive communication devices, or sensory accommodations while awaiting more targeted options.

Research Frontiers With Clear Limitations

Preclinical studies (early-stage research using animal models) have identified potential drug candidates, including findings from zebrafish studies at Yale. However, researchers caution about extrapolating these results to humans, as noted in PNAS. Other approaches like microbiota-based therapies show promise but face the challenge of autism's heterogeneity - what helps one individual may not benefit another. The THERAUTISM Project is among several initiatives working to bridge this translational gap.